S alt-sensitive (SS) hypertension is characterized by increases in blood pressure in response to elevations of dietary salt intake and by immune responses that play a key role in the pathophysiology of disease.
S alt-sensitive (SS) hypertension is characterized by increases in blood pressure in response to elevations of dietary salt intake and by immune responses that play a key role in the pathophysiology of disease. 1, 2 Renal inflammation is a common feature of experimental and clinical hypertensions, with lymphocytes and macrophages localizing to regions of renal injury. 2, 3 In the commonly used Dahl SS rat, it has been shown that renal inflammation amplifies the hypertension and renal damage, 4 ,5 similar to observations obtained from hypertensive patients. 1, 6 It has also been recognized that renal hypertrophy and cell proliferation are importantly associated with hypertension and kidney injury in SS rats. 7, 8 The present study focused on the role of the mTORC1 (mammalian target of rapamycin complex 1) in blood pressure salt sensitivity and renal injury in SS rats. mTOR is a serine/ threonine kinase with 2 structurally and functionally distinct multiprotein complexes, mTORC1 and mTORC2 that correspond to 2 major branches of the overall pathway. mTORC1 is composed of mTOR and several subunits (notably Raptor) and serves as a master growth regulator that senses and integrates diverse cues, such as insulin/insulin-like growth factor, amino acids, and energy stress and thus regulates several cellular processes, such as cell proliferation, hypertrophy, and immune cells proliferation.
9 mTORC1 controls protein synthesis by phosphorylating and activating the ribosomal protein S6 kinase. 10 S6 kinase phosphorylates C-terminal serine sites at the position of S235 and S236 of ribosomal protein S6, and pS6 S235/236 /S6 is measured as a surrogate marker of mTORC1 activity. 11 Phosphorylation of AKT at serine473 has been shown to be directly activated by mTORC2, and pAKT S473 / AKT is the canonical readout of mTORC2 activity. 12 A rich body of literature reports the effect of the mTORC1 inhibitor rapamycin in blocking cell proliferation in cancer, 13 reducing ventricular hypertrophy, 14 and attenuating immune responses in the kidney transplantation field. 15 Interestingly, given the recognized immune/inflammation components of hypertension, it is remarkable that this pathway has not been meaningfully explored in this disease. 14, 16 The present study, therefore, assessed the role of mTORC1 in the development of salt-induced hypertension and kidney injury in SS rats. The specific mTORC1 inhibitor rapamycin was used, which significantly attenuated hypertension, kidney injury, immune cells infiltration, renal hypertrophy, and cell proliferation in SS rats.
Abstract-The goal of the present study was to explore the protective effects of mTORC1 (mammalian target of rapamycin complex 1) inhibition by rapamycin on salt-induced hypertension and kidney injury in Dahl salt-sensitive (SS) rats. We have previously demonstrated that H 2 O 2 is elevated in the kidneys of SS rats. The present study showed a significant upregulation of renal mTORC1 activity in the SS rats fed a 4.0% NaCl for 3 days. In addition, renal interstitial infusion of H 2 O 2 into salt-resistant Sprague Dawley rats for 3 days was also found to stimulate mTORC1 activity independent of a rise of arterial blood pressure. Together, these data indicate that the salt-induced increases of renal H 2 O 2 in SS rats activated the mTORC1 pathway. Daily administration of rapamycin (IP, 1.5 mg/kg per day) for 21 days reduced saltinduced hypertension from 176.0±9.0 to 153.0±12.0 mm Hg in SS rats but had no effect on blood pressure salt sensitivity in Sprague Dawley treated rats. Compared with vehicle, rapamycin reduced albumin excretion rate in SS rats from 190.0±35.0 to 37.0±5.0 mg/d and reduced the renal infiltration of T lymphocytes (CD3 + ) and macrophages (ED1 + ) in the cortex and medulla. Renal hypertrophy and cell proliferation were also reduced in rapamycin-treated SS rats. We conclude that enhancement of intrarenal H 2 O 2 with a 4.0% NaCl diet stimulates the mTORC1 pathway that is necessary for the full development of the salt-induced hypertension and kidney injury in the SS rat. (Hypertension. 2017;70:813-radiotelemetry catheters and transmitters were surgically implanted for recording 24 h/d blood pressure and heart rate. Daily body weight was measured to adjust the daily dose of rapamycin. On the final day of the 4.0% NaCl diet period, rats were placed in a metabolic cage for a 24-hour urine collection. As described previously, 18 unilaterally nephrectomized SD rats were prepared with a renal interstitial catheter, as well as a femoral arterial catheter, to infuse H 2 O 2 (347 nmol·kg
) for 3 days with the rats fed a 0.4% salt diet. Immunohistochemistry, TUNEL (terminal deoxynucleotidyl transferase [TdT] dUTP nick-end labeling), Western blot, renal tubular injury, and glomerular score were performed as we have described. 7, 17, 19 Detailed experimental methods and description of antibodies are available in the online-only Data Supplement.
Statistical Methods
Data are presented as mean values±SE. A 2-way ANOVA for repeated measures test was used for blood pressure analysis. Student t test was used to compare between the 2 treatments. Paired t test was used to compare the effect of treatments on body weight of SS rats fed a 4.0% NaCl diet. P<0.05 was considered significant. /S6 normalized to the saline-treated SD rats. Saline (n=4) and H 2 O 2 (n=5). *P<0.05.
Results

Upregulation
S6 was increased significantly in the cortex of SS rats fed a 4.0% NaCl diet as early as day 3, rose further by day 14, and reached to the maximum at day 21 compared with 0.4% fed rats ( Figure 1A ). SD rats, in contrast, exhibited a progressive reduction in the cortical pS6 S235/236 /S6, which was significantly suppressed by day 21 of the 4.0% NaCl diet ( Figure 1B ). Immunohistochemical analysis qualitatively confirmed the elevation of pS6 S235/236 in the cortex and medulla of SS rats fed a 4.0% NaCl for 21 days ( Figure 1C ). By immunohistochemistry, it was found that pS6 S235/236 was ubiquitously present in the kidneys of SS rats fed a 0.4% NaCl diet, which includes glomerulus, proximal convoluted tubules, medullary thick ascending limb, distal convoluted tubules, intermedullary collecting duct, interstitium space, and blood vessel ( Figure S1 in the online-only Data Supplement).
We have previously demonstrated that SS rats exhibit elevated levels of renal interstitial H 2 O 2 , and additionally salt sensitivity was mimicked in salt-resistant SS. 13 BN rats by chronic renal interstitial infusion of H 2 O 2 (347 nmol/kg per minute) comparable to those observed in 4.0% NaClfed SS rats. 18 In the present studies, this same dose of H 2 O 2 was infused continuously for 3 days into the renal interstitium of unilaterally nephrectomized SD rats maintained on 0.4% NaCl diet to determine whether these elevations would stimulate the mTORC1 activity. Figure 1D shows significant increases of pS6 S235/236 /S6 in the medulla of these SD rats compared with saline-infused control rats, indicating that H 2 O 2 serves as an important upstream mediator of the mTORC1 pathway in vivo.
Effect of Rapamycin on Mean Arterial Pressure, Albumin and Protein Excretion Rate, and Glomerular Injury
As summarized in Figure 2 , the daily mean 24-hour arterial pressure (MAP) of SS rats treated with rapamycin (IP, 1.5 mg/kg per day) averaged 128.0±2.0 mm Hg during the 4 days before drug treatment and rose to 139.0±2.0 mm Hg by the end of the first 4 days of drug treatment (P<0.05) maintained on 0.4% NaCl diet. Vehicle-treated SS rats that averaged 126.0±2.0 mm Hg during the 4 days control period exhibited no change in MAP throughout this same period. MAP of vehicle-treated rats increased to 153.0±2.0 mm Hg by day 10 of the 4.0% NaCl diet and then rose progressively to levels averaging 176.0±3.0 mm Hg on day 21 of 4.0% NaCl. In contrast, MAP of rapamycin-treated rats rose only slightly during the first 10 days after switching to the 4.0% NaCl diet and thereafter increased only gradually to an average MAP of 153.0±4.0 mm Hg by day 21, values significantly less (P<0.05) than the vehicle-treated rats. Rapamycin nearly abolished diurnal variations of MAP, diastolic blood pressure, and systolic blood pressure, changes that were apparent even during the first day of treatment shown in Figure S2A -S2C. Heart rate diurnal variations reduced slowly and sustained throughout the study period in the treated rats ( Figure S2D ).
During the study, the animals were closely monitored noting appearance of eyes and fur, grooming, appetite, behavior, body weight, and activity. Rapamycin-treated SS rats did not exhibit a gain of body weight averaging 307±4 g at control and 302±8 g after 3-week period of treatment and was also less than the vehicle-treated rats (347±8 versus 302±8 g; P<0.05). Neither the average total food intake nor the steadystate levels of Na + excretion differed significantly between rapamycin-and vehicle-treated SS rats during 4.0% NaCl diet period ( Figure S3A and S3B). Both rapamycin-and vehicle-treated rats appeared active and healthy throughout the study based on the above-mentioned assessed parameters of well-being.
SD rats were studied in the same manner. As with SS rats, MAP was increased on average ≈10 mm Hg by day 4 of rapamycin treatment during the period of 0.4% NaCl diet ( Figure 2 ). However, a similar rise of MAP was observed in vehicle-treated SD rats, suggesting a vehicle-dependent response. In contrast to SS rats, rapamycin-treated SD rats exhibited a gain in the body weight from 304±8 to 324±11 g (P<0.05) during the 21 days of the 4.0% NaCl diet although neither daily food intake nor steady-state Na + excretion was altered ( Figure S3C and S3D) . However, when compared with vehicle-treated SD rats, body weight of rapamycintreated rats was lower at the end of study (324±11 versus 365±2 g; P<0.05). As seen in SS rats, rapamycin abolished the diurnal variations of MAP, systolic blood pressure, and diastolic blood pressure but had little effect on diurnal variations of heart rate in SD rats ( Figure S2E-S2H ). Albumin excretion rate was unaltered between the vehicle-(26.6±23.6 mg/d) and rapamycin-treated (11.7±2.3 mg/d) SD rats.
Also seen in Figure 3A , treatment with rapamycin decreased the kidney injury in SS rats as reflected by albumin excretion rate (U alb V) from 190.0±35.0 to 37.0±5.0 mg/d compared with vehicle-treated rats. Similar responses were observed as determined with urine protein excretion rate ( Figure 3B ). Protection from renal tubular injury in rapamycin-treated rats was evident based on the significant reduction of tubular protein casts within the outer medulla ( Figure 3C) . Importantly, the glomerular injury index was significantly reduced in the kidney of rapamycin-treated rats compared with vehicle-treated SS rats ( Figure 3D ).
Rapamycin Specifically Inhibited Renal mTORC1 Activity
Rapamycin-treated rats exhibited ≈2-fold reduction in the level of pS6 S235/236 /S6 in both cortex and outer medulla relative to vehicle-treated rats ( Figure 4A ). These reductions were consistent with the immunohistochemical analysis of pS6 S235/236 in both cortex and medulla of these kidneys represented in Figure 4B . In contrast, pAKT S473 /AKT remained unaffected in both cortex and outer medulla of these rats kidney ( Figure 4C ). These data indicate that the rapamycin specifically inhibited the renal mTORC1 activity and that the protective effect on salt-induced hypertension and renal injury observed with rapamycin treatment was independent of any possible off target inhibition of renal mTORC2 activity. Moreover, both T lymphocyte and macrophage markers (CD3 and CD68, respectively) were found to be colocalized with pS6 S235/236 in the kidney of SS rats fed a 4.0% NaCl diet for 21 days ( Figure S4 ).
Rapamycin Reduced the Renal Hypertrophy and Cell Proliferation Independent of Apoptosis
The ratio of kidney weight to body weight was determined to obtain hypertrophy index, and p27 (cyclin-dependent kinase inhibitor) and Ki67 were used as a marker to assess hypertrophic and proliferative cells, respectively. As summarized in Figure 6A , rapamycin lowered the hypertrophy index by 28.0% (P<0.05) compared with vehicle-treated SS rats. Consistent with this observation, rapamycin reduced the percentage of p27-labeled cells by 50% in both cortex and outer medulla. (Figure 6B ; Figure S5 ). The immunohistochemical analysis of Ki67-labeled cells in the kidney demonstrated that rapamycin significantly reduced the percentage of Ki67-labeled cells in the cortex from 11.0±4.0 to 3.0±1.0 and in the outer medulla from 9.0±2.0 to 2.0±1.0 compared with vehicletreated rats ( Figure 6C ; Figure S6 ). To assess the contribution of apoptosis to the observed reduction of proliferative cells, TUNEL immunohistochemical analysis for apoptosis was performed. As shown in Figure 6D and Figure S7 , although the outer medulla exhibited greater levels of apoptosis than the cortex, neither rapamycin nor vehicle treatment had any effect in either region.
Discussion
The present studies found that the inhibition of mTORC1 pathway with rapamycin significantly attenuated the salt-induced hypertension and effectively protected against renal injury in SS rats. mTORC1 is ubiquitously expressed in the kidney as reflected in Figure 1C and Figure S1 , and this signaling pathway has been studied in several human diseases, such as diabetes mellitus, where it seems to play a role in podocyte function and diabetic nephropathy in humans and mice. 20, 21 Although there have been remarkably few studies examining the effects of mTORC1 inhibition in hypertension, an upregulation of PI3K (phosphoinositide 3-kinase)/Akt/mTOR pathway has been observed in a deoxycorticosterone-salt model of hypertension 22 and in Han:SPRD rats with polycystic kidney disease. 23 In the present study, an elevation of mTORC1 activity in the kidneys of SS rats fed a 4.0% NaCl diet was reflected by significant increases of pS6 S235/236 /S6 ( Figure 1A ). In the SS rats, high salt intake is known to increase in the production of reactive oxygen species, including superoxide O 2 -24 and H 2 O 2 18 in the kidney from NADPH (nicotinamide adenine dinucleotide phosphate) oxidases and mitochondria. 17, 25 There is growing recognition that H 2 O 2 is not simply a by-product of metabolism, but it acts as a secondary messenger with active roles in signaling processes. 25 S6 kinase activity levels have been found to be stimulated by H 2 O 2 treatment of mouse epidermal JB6 cells in a dose-and time-dependent manner. 26 The present chronic infusion studies importantly demonstrated the in vivo relevance of H 2 O 2 stimulation of the mTORC1 pathway in the kidney. The amount of H 2 O 2 delivered into the renal interstitium of SD rats in the present study produces tissue concentrations similar to those found in SS rats fed a high salt diet. 18 Because these chronic elevations of H 2 O 2 elevated the renal tissue activity of pS6 S235/236 /S6, it seems that the elevations of renal H 2 O 2 observed in the SS rats fed the 4.0% NaCl diet would serve as a secondary messenger to upregulate mTORC1 activity and dysregulation of mTORC1-mediated cellular processes.
We have observed a moderate initial rise of blood pressure during the 4 days of rapamycin treatment while both SS and SD rats received a 0.4% NaCl diet before switching to the 4.0% NaCl diet, a response also reported in Wistar rats treated with rapamycin for 7 weeks. 27 The mechanism(s) responsible for this rise of pressure remain unclear. Central neural actions of rapamycin are suggested by observed alterations of circadian rhythms. Cao et al 28 recently reported that the mTORC1 pathway serves as a potent and selective regulator of lightevoked protein translation and suprachiasmatic nucleus clock entrainment. Consistent with their observations, we found that the diurnal blood pressure rhythm was nearly abolished in rapamycin-treated SS and SD rats, which was apparent as early as 12 hours after start of drug treatment.
Immune Cell Participation in Salt-Induced Hypertension and Kidney Injury
The most important observation of the present study is that the malignant phase of the hypertension was prevented by rapamycin treatment of SS rats fed a 4.0% NaCl diet. Among the most important mechanisms to consider when inhibiting the mTORC1 pathway are those related to both the innate (macrophages) and adaptive immune cells (T lymphocytes) that reside in the kidney and which are known to amplify the disease process in both SS rats and humans.
2 Phospho-S6 was colocalized with T lymphocytes and macrophages in our study, suggesting that protective effects of rapamycin were a consequence of actions on both infiltrated immune cells and glomeruli/tubules mTORC1. Treatment with the immunosuppressant tacrolimus has been shown to attenuate salt-induced hypertension in SS rats by preventing immune cells infiltration. 4 However, tacrolimus as other similar compounds, such as cyclosporine, are nephrotoxic as a consequence of vasoconstriction of the afferent and efferent glomerular arterioles. 13 In contrast, rapamycin seems to exhibit minimal vasomotor renal side effects as observed with chronic treatment of spontaneously hypertensive rats (SHR) in which no changes of glomerular filtration or renal blood flow were observed. 29 In vehicle-treated SS rats, on switching to the 4.0% NaCl diet, there was a rapid initial rise of blood pressure followed by a more dramatic rise of pressure after 10 to 14 days, which is known to be accompanied by increased infiltration of immune cells into the kidney and culminating in malignant hypertension. 4, 5 Both pharmacological and genetic approaches that reduce renal immune cells infiltration attenuate this secondary phase of salt-induced hypertension and renal injury in SS rats but not the primary phase. 5, 30 The rapamycin-treated SS rats in the present study bear similarities to the phenotype observed in SS rats in which CD247 was globally knocked out (a T lymphocytes knockout rat model) and in SS rats treated with tacrolimus. 4, 31 As seen in SS CD247−/− and tacrolimus-treated SS rats, Interestingly, increased proteinuria has been observed with chronic treatment with everolimus, a derivative of rapamycin. 33, 34 In the present study, rapamycin-treated rats exhibited 5-fold reduction of daily albumin excretion, which was an even greater response than that found in SS CD247−/− rats 31 and tacrolimus-treated rats, 4 which exhibited only a 3-fold reduction of daily albumin excretion. This greater protective effect could be explained by other mTORC1-mediated cellular processes that are important for the secondary phase of SS hypertension. For example, the proto-oncogene cancer Osaka thyroid oncogene positively controls cap-dependent mRNA translation of Tnf and Il6 through mTORC1 in mouse macrophages. 35 Interleukin-6 is a proinflammatory cytokine produced by various cells, including macrophages, T lymphocytes, endothelial cells, and vascular smooth muscle cells. 36 Chronic treatment of anti-interleukin-6 antibody reduced salt sensitivity and renal macrophage accumulation in SS rats. 3 Rapamycin inhibition of interleukin-6 expression could, therefore, also account for some of the anti-inflammatory effects of rapamycin. 10 These actions would be consistent with our observation that rapamycin-treated rats exhibited a significant reduction of macrophage infiltration into the kidney ( Figure 6B ). In this study, rapamycin was administrated systemically, so the involvement of other organs and circulating immune cells in the observed responses cannot be ruled out. Nevertheless, present studies provide a strong association of renal mTORC1 activity and immune cell infiltration in salt-induced kidney injury in SS rats.
Rapamycin Protects Kidney Injury by Inhibiting Renal Hypertrophy and Cell Proliferation
We have recently reported the increased proliferative cells in the medullary thick ascending limbs of Henle in the SS rats on a high-salt diet. 7 The development of hypertension is commonly associated with kidney hypertrophy in rodents. 8, 37 Rapamycin treatment to spontaneous hypertensive rats exhibited attenuation in cardiac hypertrophy although in that study renal hypertrophy was not studied. 14 In the present study, rapamycin inhibited renal hypertrophy and reduced cell proliferation (Ki67) in a 4.0% NaCl diet-fed SS rats, and this was associated with a significant inhibition of mTORC1 activity, each being novel findings. Although, others have observed enhancement of apoptosis by rapamycin, 38 this was not observed in our rapamycin-treated SS rats. Prolonged rapamycin treatment has also been found to reduce mTORC2 activity in cancer cell lines, 39 which could have a direct effect on apoptosis pathways, but such effects were not apparent in present study and is consistent with our observation that renal mTORC2 activity (pAKT S473 /AKT) was unchanged by rapamycin treatment.
Perspectives
The present study indicates that mTORC1 activity is upregulated in response to 4.0% NaCl diet feeding and H 2 O 2 and that this contributes significantly to hypertension and kidney injury in SS rats. The mTORC1 inhibitor rapamycin attenuated blood pressure salt sensitivity and greatly reduced kidney injury and hypertrophy as reflected by reduction of immune cells infiltration and reduced cell proliferation. Although rapamycin is undoubtedly not the drug of choice to treat hypertension given the dose limiting side effects in human studies, 40 ,41 the present studies have revealed the importance of the mTORC1 pathway in a widely used model of hypertension. New TOR kinase inhibitors are currently being developed that should be explored as potentially novel therapeutic approaches for the treatment of hypertension and associated renal injury.
